Induction of estrogen receptor α-36 expression by bone morphogenetic protein 2 in breast cancer cell lines.

The expression of estrogen receptor-α (ERα) is one of the most important diagnostic and prognostic factors of breast cancer. Recently, ERα-36 has been identified as a novel variant of ER-α. ERα-36 lacks intrinsic transcription activity and mainly mediates non-genomic estrogen signaling. Bone morphogenetic proteins (BMPs) are recognized as key factors during the control of cell fate and cancer development. However, the correlation between BMP and the ER signaling pathway remains unclear. In this study, we show that BMP2, a member of the BMP family, is a novel inducer of ERα-36 expression in breast cancer cells. As shown by western blot assays, the upregulation of ERα-36 by BMP2 was significant. In MDA-MB-231 cells which are ERα-66-negative, BMP2 was able to induce the expression of ERα-36 in a dose-dependent manner, and the RNA interference assay indicated a correlation between BMP2 and ERα-36 expression. BMP2 inhibited the growth of MCF-7 and MDA-MB-231 cells; however, the inhibitory effect was antagonized by tamoxifen, suggesting that the ER signal was involved. The growth of MDA-MB‑231 cells was stimulated by 17-β-estradiol (E2) after BMP2 induction, even though the cells were previously insensitive to E2. These results suggest that BMP2 induces ERα-36 expression and alters tumor resistance to endocrine therapy by changing the expression profile of ERs.

[1]  J. Balko,et al.  Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Matsumoto,et al.  A role for bone morphogenetic protein-4 in lymph node vascular remodeling and primary tumor growth. , 2011, Cancer research.

[3]  J. Gustafsson,et al.  The different roles of ER subtypes in cancer biology and therapy , 2011, Nature Reviews Cancer.

[4]  James Hadfield,et al.  Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells , 2011, Proceedings of the National Academy of Sciences.

[5]  松本 佳則.  Estrogen and glucocorticoid regulate osteoblast differentiation through the interaction of bone morphogenetic protein-2 and tumor necrosis factor-α in C2C12 cells , 2011 .

[6]  D. Bernard,et al.  Bone morphogenetic protein 2 acts via inhibitor of DNA binding proteins to synergistically regulate follicle-stimulating hormone beta transcription with activin A. , 2010, Endocrinology.

[7]  Nan Li,et al.  Human Phosphatidylethanolamine-binding Protein 4 Promotes Transactivation of Estrogen Receptor α (ERα) in Human Cancer Cells by Inhibiting Proteasome-dependent ERα Degradation via Association with Src* , 2010, The Journal of Biological Chemistry.

[8]  Liying Yan,et al.  ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways , 2010, PloS one.

[9]  D. Bernard,et al.  Bone Morphogenetic Protein 2 Acts via Inhibitor of DNA Binding Proteins to Synergistically Regulate Follicle-Stimulating Hormone (cid:1) Transcription with Activin A , 2010 .

[10]  Kohei Miyazono,et al.  Bone morphogenetic protein receptors and signal transduction. , 2010, Journal of biochemistry.

[11]  Yuntao Xie,et al.  Expression of ER-{alpha}36, a novel variant of estrogen receptor {alpha}, and resistance to tamoxifen treatment in breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  R. Greil,et al.  Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Yuri Kotliarov,et al.  Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. , 2008, Cancer cell.

[14]  Z. Gatalica,et al.  ER-α36, a Novel Variant of ER-α, is Expressed in ER-positive and -negative Human Breast Carcinomas , 2008 .

[15]  Z. Gatalica,et al.  ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. , 2008, Anticancer research.

[16]  S. Kilen,et al.  Activin Regulates Estrogen Receptor Gene Expression in the Mouse Ovary* , 2007, Journal of Biological Chemistry.

[17]  Xu Wang,et al.  Epigenetic regulation of bone morphogenetic protein-6 gene expression in breast cancer cells , 2007, Journal of Steroid Biochemistry and Molecular Biology.

[18]  T. Deuel,et al.  A variant of estrogen receptor-α, hER-α36: Transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling , 2006 .

[19]  T. Deuel,et al.  A variant of estrogen receptor-{alpha}, hER-{alpha}36: transduction of estrogen- and antiestrogen-dependent membrane-initiated mitogenic signaling. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  E. Ariazi,et al.  ERE-independent ERα target genes differentially expressed in human breast tumors , 2005, Molecular and Cellular Endocrinology.

[21]  T. Deuel,et al.  Identification, cloning, and expression of human estrogen receptor-α36, a novel variant of human estrogen receptor-α66 , 2005 .

[22]  J. Wrana,et al.  The disparate role of BMP in stem cell biology , 2005, Oncogene.

[23]  D. Edwards.  Regulation of signal transduction pathways by estrogen and progesterone. , 2005, Annual review of physiology.

[24]  T. Deuel,et al.  Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. , 2005, Biochemical and biophysical research communications.

[25]  E. Ariazi,et al.  ERE-independent ERalpha target genes differentially expressed in human breast tumors. , 2005, Molecular and cellular endocrinology.

[26]  S. Fuqua,et al.  Estrogen receptor mutations in human disease. , 2004, Endocrine reviews.

[27]  M. Goumans,et al.  Controlling cell fate by bone morphogenetic protein receptors , 2003, Molecular and Cellular Endocrinology.

[28]  W. Grizzle,et al.  Smad4 as a Transcription Corepressor for Estrogen Receptor α* , 2003, The Journal of Biological Chemistry.

[29]  Tetsuya Yamamoto,et al.  Cross-talk between bone morphogenic proteins and estrogen receptor signaling. , 2002, Endocrinology.

[30]  Jeffrey L. Wrana,et al.  Signal Transduction by the TGF-β Superfamily , 2002, Science.

[31]  J. Wrana,et al.  Signal transduction by the TGF-beta superfamily. , 2002, Science.

[32]  D. Pfaff,et al.  Early membrane estrogenic effects required for full expression of slower genomic actions in a nerve cell line , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Benita S Katzenellenbogen,et al.  Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta - regulation by selective estrogen receptor modulators and importance in breast cancer , 2000, Breast Cancer Research.

[34]  R. Oreffo,et al.  Human bone marrow osteoprogenitors express estrogen receptor‐alpha and bone morphogenetic proteins 2 and 4 mRNA during osteoblastic differentiation , 1999, Journal of cellular biochemistry.

[35]  Osborne Ck,et al.  Tamoxifen in the Treatment of Breast Cancer , 1998 .

[36]  C. Osborne,et al.  Tamoxifen in the treatment of breast cancer. , 1998, The New England journal of medicine.

[37]  V. Rosen,et al.  Novel regulators of bone formation: molecular clones and activities. , 1988, Science.